Eden Innovations Flags Early India Trial Gains For EdenCrete Pz7 High-Strength Concrete

Eden Innovations (ASX: EDE) says early India trial work for its EdenCrete Pz7 concrete additive is showing a 28% reduction in abrasion in road mixes and 10% to 20% extra strength in high-strength concrete.

Eden is building technical evidence for potential use in large Indian infrastructure and high-rise applications, although the work remains at trial stage rather than contracted commercial rollout.

The program is centred on the Delhi area and involves ready-mix companies, high-rise developers and CRRI, which the company described as a national laboratory under CSIR.

EdenCrete Pz7 is one of Eden’s concrete additive products, used in mix designs to improve performance characteristics while potentially changing the balance of other ingredients.

The company is positioning the additive for two distinct uses: road concrete where abrasion resistance matters, and high-strength concrete of 50 MPa+ where mix cost and strength margins are critical.

Eden said the road mix work delivered 28% lower abrasion at low-cost dosages, while also reporting 10% to 20% extra strength compared with the original versions of those mixes.

Those strength gains may allow lower inputs of ordinary Portland cement, or OPC, and micro-silica, while increasing the use of supplementary cementitious materials such as fly ash or slag and the potential for a lower CO2 footprint for concrete mixes.

Dual Commercialisation Pathway

The India trials sit within Eden’s broader push to commercialise EdenCrete Pz7 across multiple regions.

Previous company updates show the additive has also been rolled out through plant installations and supply arrangements in North and South America, including additional requests from Amrize in Colorado and supply to Holcim Ecuador plants since 2024.

In India, the current test work is aimed at two large end markets.

The first is transport infrastructure, particularly roads and bridge-related concrete.

The company cited Indian infrastructure spending allocation of 12.2 trillion INR for FY2026-27, about 50,000 kilometres of concrete highway built since 2014, and roughly 100,000 kilometres of highways overall including asphalt.

The second is high-rise construction, with Eden pointing to reinforced cement concrete use at building heights of roughly 250 metres to 300 metres as evidence of an addressable ready-mix market where high-strength mix design matters.

The company’s argument is that if EdenCrete Pz7 provides a strength buffer, ready-mix producers or developers may be able to rebalance expensive ingredients in those mixes.

CRRI’s involvement is a key part of the backdrop because it gives the program a government-linked testing pathway.

EdenCrete products are being tested by CRRI in M60 grade concrete for bridge overlay and UTWT-style repairs, and in M40 pavement quality concrete, with further trials scheduled.

Numbers and Study Scope

The two central numbers in the announcement were the 28% abrasion reduction in road mixes and the 10% to 20% strength increase in high-strength concrete mixes above 50 MPa.

The strength uplift matters because it may support reductions in higher-cost ingredients including OPC and micro-silica, with replacement by supplementary cementitious materials such as fly ash or slag.

In other words, the product is being presented as a tool to improve the economics and emissions profile of a mix, not just to maximise headline strength.

The filing also cited CRRI and Indian Roads Congress guideline ranges for supplementary materials in highways and bridge construction of 15% to 30% for fly ash replacement and 50% to 70% for slag, or GGBS, replacement.

Eden’s case is that EdenCrete Pz7 may help support these more SCM-heavy formulations without sacrificing performance.

What Comes Next

Beyond the scheduled further CRRI testing, the practical questions are whether the trial outcomes can be repeated across more mixes, more customers and more regions, and whether they move through accepted testing and procurement pathways.

Eden intends to expand trials in Delhi and other Indian regions with significant high-rise activity, and to increase staff count to accommodate increased interest.

That makes execution the main point to watch.

The company’s own disclosure noted that the work is still early and continuing, and that the filing does not provide finalised verification, independent certification detail, durability and regulatory pass-through, pricing or volume commitments.

Funding also remains part of the wider picture. While Eden has raised capital this year, context filings show the company has also used option-based incentives and placement-related securities in support of its broader strategy.

As a result, any progress in India is likely to be assessed alongside cash usage, staffing expansion and evidence that technical trial work is becoming disclosed commercial business.